For example, the daVinci surgical robot can mean smaller incisions, less post-operative pain and faster recovery times. Scottsdale Healthcare has the longest experience with the daVinci robot of any Arizona hospital, acquiring the state's first daVinci in 2001. Our clinical staff are experts in the areas of GYN/Oncology, Colerectal, Gynecology and Urology using this technology.
Scottsdale Healthcare also:
- Performed Arizona’s first heart procedure using the infrared and fiber optic technology of the LipiScan Coronary Imaging System, which detects hard-to-find artery blockage.
Just as there are smart cars and smart phones, there is now a “smart” operating room at Scottsdale Healthcare Osborn Medical Center.Known as a Hybrid Operating Room (OR), this state-of-the-art surgical suite combines radiology, a cardiac catheterization lab and surgery all in one room for heart and vascular patients.In the Hybrid OR, the patient stays in one place with the interventional cardiologists, electrophysiologists or interventional radiologists and heart and vascular surgeons all working side-by-side in the same room, at the same time. If a patient is undergoing a cardiac catheterization procedure and it becomes necessary to perform a surgical procedure, the patient doesn’t have to be moved.With ceiling-mounted equipment and more than 800 square feet, the futuristic OR is twice the size of a traditional operating room and offers an open and spacious environment with the latest equipment for high-quality imaging with in-depth 3-D visualization.
Open-Chest Surgery Not Required- Transcatheter Aortic Valve Replacement (TAVR)
Scottsdale Healthcare is proud to announce it is among one of the first United States hospitals approved to perform a new nonsurgical heart valve replacement procedure inside the new Hybrid OR, the Transcatheter Aortic Valve Replacement (TAVR). TAVR is significant because it does not require open-chest surgery, giving hope to heart patients with inoperable aortic stenosis.A catheter fed through the femoral artery is used to implant the Edwards™ SAPIEN Transcatheter Aortic Heart Valve, which recently received FDA approval for commercial use in the United States.Patients with inoperable aortic stenosis tend to be older and sicker, often with multiple additional health issues complicating their condition. The TAVR procedure gives hope for extending the lives of these patients with improved quality of life.
New ‘Disappearing Stent’ Restores Blood Flow to Hearts
Scottsdale Healthcare is first in region to implant investigational device in patients with clogged arteries. A dissolvable stent that opens clogged arteries in the heart has researchers at Scottsdale Healthcare encouraged that it may become a game changing technology for treating the symptoms of coronary artery disease (CAD), the most common type of heart disease.The Absorb Bioresorbable Vascular Scaffold (BVS), is a small mesh tube made of polylactide, a material that is commonly used in medical implants such as dissolvable sutures. Absorb is coated with a medication which reduces inflammation and tissue growth to help prevent renarrowing of the artery.The scaffold restores blood flow and provides support to the vessel until the artery can stay open on its own. It dissolves over time, potentially allowing the vessel to resume more natural function and movement. The idea of moving away from permanent metal implants to literally disappearing implants is a quantum leap forward for our heart patients at Scottsdale Healthcare. The cardiology team of physicians, nursing staff and clinicians are extremely pleased to participate in the trial of this latest advancement to our community.
Scottsdale Healthcare is currently accepting new patients to enroll in the ABSORB III clinical trial. The clinical trial is evaluating potential benefits of Absorb in comparison to the leading metallic drug eluting stent in patients with CAD, the most common cause of death for men and women in the United States. Absorb is authorized for sale in CE Mark countries and is available in Europe, the Middle East, parts of Latin America, and parts of Asia Pacific, including India, Hong Kong, Malaysia and New Zealand.
For more information about enrolling in this clinical trial, contact the Scottsdale Healthcare Research Institute at 480-323-3437.